{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:05:07Z","timestamp":1762866307029},"reference-count":68,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.antiviral.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T10:31:17Z","timestamp":1390645877000},"page":"34-39","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["What is the future of ribavirin therapy for hepatitis C?"],"prefix":"10.1016","volume":"104","author":[{"given":"Christopher","family":"Koh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Jake","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.01.005_b0010","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0340","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.23073","article-title":"A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results","volume":"50","author":"Benhamou","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0345","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.1840160307","article-title":"A pilot study of ribavirin therapy for chronic hepatitis C","volume":"16","author":"Di Bisceglie","year":"1992","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","article-title":"A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C","volume":"107","author":"Brillanti","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.005_b0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jac\/dkh126","article-title":"Implications of finding synergic in vitro drug\u2013drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus","volume":"53","author":"Buckwold","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 2","key":"10.1016\/j.antiviral.2014.01.005_b0035","first-page":"8","article-title":"The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C","volume":"23","author":"Chemello","year":"1995","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0040","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1128\/JVI.00382-07","article-title":"Analysis of ribavirin mutagenicity in human hepatitis C virus infection","volume":"81","author":"Chevaliez","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0350","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.22070","article-title":"Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop","volume":"47","author":"Chung","year":"2008","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0050","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-123-12-199512150-00001","article-title":"Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Di Bisceglie","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0055","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/JVI.02778-12","article-title":"Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients","volume":"87","author":"Dietz","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study","volume":"25","author":"Dusheiko","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"Management of hepatitis C virus infection","volume":"55","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0070","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.1016\/S0168-8278(13)61422-1","article-title":"Interim analysis of an interferon (IFN)- and ribavirin (RBV)- free regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C Virus genotype 1-infected patients","volume":"58","author":"Everson","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0355","article-title":"Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection","volume":"58","author":"Everson","year":"2013","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"154\u201362","key":"10.1016\/j.antiviral.2014.01.005_b0080","first-page":"e4","article-title":"Ribavirin improves early responses to peginterferon through improved interferon signaling","volume":"139","author":"Feld","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.005_b0085","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.01.005_b0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0360","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0365","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0105","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1001\/jama.1983.03330430042027","article-title":"Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults","volume":"249","author":"Hall","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2014.01.005_b0110","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s10620-010-1504-y","article-title":"U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for \u201cdifficult-to-treat\u201d HCV genotype 1 patients","volume":"56","author":"Ho","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.antiviral.2014.01.005_b0120","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1053\/j.gastro.2006.12.005","article-title":"Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy","volume":"132","author":"Hofmann","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.005_b0125","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.01.005_b0370","first-page":"234","article-title":"First Report of Peginterferon Lambda\/Ribavirin in Combination With Either Daclatasvir or Asunaprevir in HCV Genotype 1 Japanese Subjects: Early Sustained Virologic Response (SVR4) Results from the D-LITE Japanese Substudy","volume":"56","author":"Izumi","year":"2012","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0375","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.21670","article-title":"Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1","volume":"46","author":"Jacobson","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0145","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0380","first-page":"308a-a","article-title":"VX-222, telaprevir and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen","volume":"56","author":"Jacobson","year":"2012","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0150","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0155","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2010.08.002","article-title":"Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection","volume":"139","author":"Kamar","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2014.01.005_b0385","first-page":"1289","article-title":"Ribavirin in the treatment of SARS: A new trick for an old drug?","volume":"168","author":"Koren","year":"2003","journal-title":"CMAJ"},{"key":"10.1016\/j.antiviral.2014.01.005_b0390","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(13)60005-7","article-title":"Safety and Efficacy of Interferon-Free Regimens of ABT-450\/r, ABT-267, ABT-333 +\/\u2212 Ribavirin in Patients with Chronic HCV GT1 Infection: Results from the AVIATOR Study","volume":"58","author":"Kowdley","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0170","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJMc1307641","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"369","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","article-title":"A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1","volume":"59","author":"Lawitz","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0395","first-page":"244A","article-title":"High efficacy and safety of the all-oral combination regimen, MK-5172\/MK-8742 +\/\u2212 RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study","volume":"58","author":"Lawitz","year":"2013","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b9000","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","author":"Lawitz","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.antiviral.2014.01.005_b0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-8278(98)80175-X","article-title":"Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus","volume":"29","author":"Lee","year":"1998","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0190","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","article-title":"Current and future therapies for hepatitis C virus infection","volume":"368","author":"Liang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0091270004262974","article-title":"Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers","volume":"44","author":"Lin","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0400","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":"High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0205","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0405","first-page":"230-a","article-title":"Sustained Virological Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV;NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor With or Without Peginterferon Alfa-2a\/Ribavirin (PEG\/RBV)","volume":"56","author":"Lok","year":"2012","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2009.10.015","article-title":"Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients","volume":"52","author":"Marcellin","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0225","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0230","first-page":"537827","article-title":"Retreatment of patients nonresponsive to pegylated interferon and ribavirin with daily high-dose consensus interferon","volume":"2010","author":"Meyer","year":"2010","journal-title":"Hepatitis Res. Treat."},{"key":"10.1016\/j.antiviral.2014.01.005_b0410","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0240","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2014.01.005_b0245","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular mechanisms of action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.01.005_b0415","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.23827","article-title":"Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C","volume":"52","author":"Poordad","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.005_b0005","unstructured":"Rebetol \u00ae [package insert]. In: Merck, (Ed.), Whitehouse Station, NJ: Merck, 2013."},{"key":"10.1016\/j.antiviral.2014.01.005_b0265","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.antiviral.2014.01.005_b0420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/gutjnl-2012-303852","article-title":"Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C","volume":"63","author":"Rotman","year":"2014","journal-title":"Gut."},{"key":"10.1016\/j.antiviral.2014.01.005_b0425","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0430","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0285","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.1016\/S0168-8278(13)61416-6","article-title":"Sustained virological response with daclatasvir plus sofosbuvir +\/\u2212 ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC)","volume":"58","author":"Sulkowski","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0290","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S0168-8278(11)60478-9","article-title":"Anemia during treatment with peginterferon alfa-2B\/ribavirin with Or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients","volume":"54","author":"Sulkowski","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0295","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/S0168-8278(11)60479-0","article-title":"Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the advance and illuminate phase 3 studies","volume":"54","author":"Sulkowski","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0300","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0435","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.23985","article-title":"Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0310","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1440-1746.1994.tb01566.x","article-title":"Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin","volume":"9","author":"Tong","year":"1994","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0440","article-title":"Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study","volume":"56","author":"Vierling","year":"2012","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0320","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkg405","article-title":"Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design","volume":"52","author":"Wu","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2014.01.005_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2013.12.006","article-title":"Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH\u2013C)","author":"Younossi","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.01.005_b0450","first-page":"733A","article-title":"Sofosbuvir + ribavirin for 12 or 24 wrrks for patients with HCV genotype 2 or 3: the VALENCE trial","volume":"58","author":"Zeuzem","year":"2013","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.antiviral.2014.01.005_b0335","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N. Engl. J. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T03:20:23Z","timestamp":1538882423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":68,"alternative-id":["S0166354214000175"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the future of ribavirin therapy for hepatitis C?","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}